Core Viewpoint - The article discusses the best ASX stocks to buy, highlighting the impact of interest rate trends in Australia and the performance of specific biotechnology companies [1][2][3]. Interest Rate Trends - The Reserve Bank of Australia (RBA) Governor Michele Bullock indicated that there are no foreseeable interest rate cuts, suggesting a potential for rate hikes in the future [2][3]. - Bullock's comments surprised many, as she clearly signaled that further interest rate cuts are off the table, preparing the market for a possible tightening bias [3]. Company Highlights Immuron Limited (NASDAQ:IMRN) - Immuron Limited is a biotechnology company focused on preventing diarrhea and developing similar medicines [8]. - The company faced a significant setback with a 25.8% drop in share price after a clinical trial for its ETEC hyperimmune bovine colostrum product failed to meet its primary endpoint [8]. - Despite the setback, the FDA cleared Immuron's IMM-529 drug for a phase 2 clinical trial, targeting Clostridioides difficile infection, with the study expected to start in the first half of 2026 [9]. Radiopharm Theranostics Limited (NASDAQ:RADX) - Radiopharm Theranostics Limited is developing treatments for conditions such as brain metastasis and prostate cancer [10]. - B. Riley lowered its price target for Radiopharm to $13 from $15 while maintaining a Buy rating, citing important clinical progress for its RAD 101 and RAD 204 compounds [10]. - RAD 204's phase 1 clinical trial showed promising results, and RAD 101 is currently in a Phase 2b trial with FDA Fast Track Designation, targeting a market of 300,000 annual diagnoses of cerebral metastases in the US [11].